| Q36168870 | A novel monoclonal antibody against mouse B7-H3 developed in rats |
| Q38036543 | A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. |
| Q38966400 | Aberrant expression of B7-H3 in gastric adenocarcinoma promotes cancer cell metastasis |
| Q28270261 | Antibody drug-conjugates targeting the tumor vasculature: Current and future developments |
| Q64113274 | Association of increased B7 protein expression by infiltrating immune cells with progression of gastric carcinogenesis |
| Q37738088 | B7-H3 Promotes the Migration and Invasion of Human Bladder Cancer Cells via the PI3K/Akt/STAT3 Signaling Pathway |
| Q33967711 | B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients |
| Q36640287 | B7-H3 and B7-H4 are independent predictors of a poor prognosis in patients with pancreatic cancer |
| Q36288654 | B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome |
| Q47138333 | B7-H3 combats apoptosis induced by chemotherapy by delivering signals to pancreatic cancer cells |
| Q39524901 | B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes |
| Q34446315 | B7-H3 expression in breast cancer and upregulation of VEGF through gene silence |
| Q34105913 | B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome |
| Q54391859 | B7-H3 expression in gastric cancer: a novel molecular blood marker for detecting circulating tumor cells. |
| Q47233613 | B7-H3 in tumors: friend or foe for tumor immunity? |
| Q39325949 | B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence |
| Q34935785 | B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis |
| Q33703916 | B7-H3 overexpression in pancreatic cancer promotes tumor progression |
| Q42700893 | B7-H3 promotes gastric cancer cell migration and invasion |
| Q90681858 | B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3 |
| Q89457607 | B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models |
| Q53238384 | B7-H3 was highly expressed in human primary hepatocellular carcinoma and promoted tumor progression. |
| Q38135281 | B7-H3-mediated tumor immunology: Friend or foe? |
| Q54586743 | B7-H6 protein expression has no prognostic significance in human gastric carcinoma. |
| Q34356712 | B7-h3 and its role in antitumor immunity |
| Q57176931 | B7H3 As a Promoter of Metastasis and Promising Therapeutic Target |
| Q35751840 | Breast Cancer Detection by B7-H3-Targeted Ultrasound Molecular Imaging |
| Q37424100 | Clinical importance of B7-H3 expression in human pancreatic cancer |
| Q37269305 | Clinical significance of the induction of macrophage differentiation by the costimulatory molecule B7-H3 in human non-small cell lung cancer |
| Q93052852 | Clinicopathological and Prognostic Characteristics of CD276 (B7-H3) Expression in Adrenocortical Carcinoma |
| Q34487698 | Combination cancer immunotherapy and new immunomodulatory targets |
| Q89558358 | Comprehensive understanding of B7 family in gastric cancer: expression profile, association with clinicopathological parameters and downstream targets |
| Q37116249 | Correlation between B7-H3 expression and matrix metalloproteinases 2 expression in pancreatic cancer |
| Q39227619 | Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis |
| Q36085671 | Differential expression of 2IgB7-H3 and 4IgB7-H3 in cancer cell lines and glioma tissues |
| Q39742066 | Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites |
| Q39500230 | Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications. |
| Q34538321 | Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients |
| Q49858189 | Expression of CD24 and B7-H3 in breast cancer and the clinical significance |
| Q33520828 | Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer |
| Q37227080 | Fine tuning the immune response through B7-H3 and B7-H4 |
| Q36207260 | Glycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response |
| Q93187257 | HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival |
| Q90442569 | HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma |
| Q93055972 | Helicobacter pylori elicits B7H3 expression on gastric epithelial cells: Implications in local T cell regulation and subset development during infection |
| Q54973593 | High expression of B7-H3 and CD163 in cancer tissues indicates malignant clinicopathological status and poor prognosis of patients with urothelial cell carcinoma of the bladder. |
| Q36444198 | Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3. |
| Q26740601 | Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? |
| Q33827752 | Inhibitors of B7-CD28 costimulation in urologic malignancies |
| Q36016292 | Inhibitory costimulation and anti-tumor immunity |
| Q37285901 | MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors |
| Q59354733 | Negative roles of B7-H3 and B7-H4 in the microenvironment of cervical cancer |
| Q36097025 | Oral Squamous Carcinoma Cells Express B7-H1 and B7-DC Receptors in Vivo |
| Q37949580 | Osteoimmunology - Unleashing the concepts |
| Q93054462 | Overexpression of B7-H3 in α-SMA-Positive Fibroblasts Is Associated With Cancer Progression and Survival in Gastric Adenocarcinomas |
| Q54442353 | Peripheral blood gene expression of B7 and CD28 family members associated with tumor progression and microscopic lymphovascular invasion in colon cancer patients. |
| Q89636157 | Porphyromonas gingivalis cell wall components induce PD-L1 expression on human oral carcinoma cells by a RIP2-dependent mechanism |
| Q37563260 | Prognostic significance of B7-H3 expression in patients with colorectal cancer: A meta-analysis |
| Q47150218 | Prognostic value of B7-H3 expression in patients with solid tumors: a meta-analysis |
| Q97537680 | Silencing of CD276 suppresses lung cancer progression by regulating integrin signaling |
| Q34577158 | T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics |
| Q38304438 | The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy |
| Q38684886 | The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1. |
| Q30318068 | The expression, function, and clinical relevance of B7 family members in cancer |
| Q39160982 | The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. |
| Q36521830 | The tumour microenvironment and implications for cancer immunotherapy |
| Q24316331 | Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses |
| Q39181190 | VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy |